Cara Therapeutics Inc (CARA)
0.6759
-0.01
(-2.04%)
USD |
NASDAQ |
Apr 19, 14:16
Cara Therapeutics Enterprise Value: -63.05M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | -63.05M |
| April 17, 2024 | -60.76M |
| April 16, 2024 | -62.01M |
| April 15, 2024 | -61.95M |
| April 12, 2024 | -59.00M |
| April 11, 2024 | -56.45M |
| April 10, 2024 | -56.38M |
| April 09, 2024 | -55.28M |
| April 08, 2024 | -55.64M |
| April 05, 2024 | -52.96M |
| April 04, 2024 | -55.62M |
| April 03, 2024 | -51.16M |
| April 02, 2024 | -50.50M |
| April 01, 2024 | -51.02M |
| March 28, 2024 | -51.02M |
| March 27, 2024 | -53.26M |
| March 26, 2024 | -60.85M |
| March 25, 2024 | -55.95M |
| March 22, 2024 | -52.48M |
| March 21, 2024 | -52.03M |
| March 20, 2024 | -51.41M |
| March 19, 2024 | -52.11M |
| March 18, 2024 | -51.16M |
| March 15, 2024 | -52.76M |
| March 14, 2024 | -57.77M |
| Date | Value |
|---|---|
| March 13, 2024 | -53.20M |
| March 12, 2024 | -52.66M |
| March 11, 2024 | -48.84M |
| March 08, 2024 | -47.12M |
| March 07, 2024 | -43.37M |
| March 06, 2024 | -46.64M |
| March 05, 2024 | -51.02M |
| March 04, 2024 | -46.11M |
| March 01, 2024 | -48.83M |
| February 29, 2024 | -54.44M |
| February 28, 2024 | -52.27M |
| February 27, 2024 | -49.25M |
| February 26, 2024 | -57.11M |
| February 23, 2024 | -51.34M |
| February 22, 2024 | -57.24M |
| February 21, 2024 | -63.92M |
| February 20, 2024 | -65.76M |
| February 16, 2024 | -66.64M |
| February 15, 2024 | -68.33M |
| February 14, 2024 | -69.97M |
| February 13, 2024 | -71.71M |
| February 12, 2024 | -69.00M |
| February 09, 2024 | -69.93M |
| February 08, 2024 | -72.42M |
| February 07, 2024 | -71.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-72.42M
Minimum
Feb 08 2024
1.289B
Maximum
Apr 09 2021
456.95M
Average
499.87M
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | -61.24M |
| Stereotaxis Inc | 186.97M |
| Cerus Corp | 312.95M |
| Avid Bioservices Inc | 522.68M |
| Rigel Pharmaceuticals Inc | 186.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.34M |
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 35.61M |
| EPS Diluted (Quarterly) | -0.60 |
| Gross Profit Margin (Quarterly) | 79.76% |
| Profit Margin (Quarterly) | -1.08K% |
| Earnings Yield | -324.0% |
| Normalized Earnings Yield | -324.01 |